DK2066354T3 - Norovirus vaccine formuleringer - Google Patents

Norovirus vaccine formuleringer

Info

Publication number: DK2066354T3
Authority: DK; Denmark
Prior art keywords: vaccine formulations; norovirus vaccine; norovirus; formulations; vaccine
Prior art date: 2006-09-29

Application number

DK07853688.5T

Other languages

English (en)

Inventor

Charles Richardson

Thomas S Vedvick

Thomas R Foubert

William T Tino

Original Assignee

Ligocyte Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-29

Filing date

2007-09-28

Publication date

2013-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2066354(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-28 Application filed by Ligocyte Pharmaceuticals Inc filed Critical Ligocyte Pharmaceuticals Inc

2013-05-27 Application granted granted Critical

2013-05-27 Publication of DK2066354T3 publication Critical patent/DK2066354T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DK07853688.5T 2006-09-29 2007-09-28 Norovirus vaccine formuleringer DK2066354T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84791206P	2006-09-29	2006-09-29
US97339207P	2007-09-18	2007-09-18
PCT/US2007/079929 WO2008042789A1 (en)	2006-09-29	2007-09-28	Norovirus vaccine formulations

Publications (1)

Publication Number	Publication Date
DK2066354T3 true DK2066354T3 (da)	2013-05-27

Family

ID=39268804

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK07853688.5T DK2066354T3 (da)	2006-09-29	2007-09-28	Norovirus vaccine formuleringer
DK13157573.0T DK2601970T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccine-formuleringer
DK13157572.2T DK2601969T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccineformuleringer

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK13157573.0T DK2601970T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccine-formuleringer
DK13157572.2T DK2601969T3 (da)	2006-09-29	2007-09-28	Norovirus-vaccineformuleringer

Country Status (16)

Country	Link
US (8)	US7955603B2 (da)
EP (4)	EP2641613A1 (da)
JP (3)	JP5476544B2 (da)
KR (1)	KR101515489B1 (da)
AU (1)	AU2007303608B2 (da)
CA (1)	CA2664157C (da)
CY (1)	CY1118492T1 (da)
DK (3)	DK2066354T3 (da)
ES (3)	ES2577833T3 (da)
HU (2)	HUE032422T2 (da)
LT (1)	LT2601970T (da)
PL (2)	PL2601969T3 (da)
PT (1)	PT2601970T (da)
SG (3)	SG10201502490YA (da)
SI (1)	SI2601970T1 (da)
WO (1)	WO2008042789A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2066354T3 (da)	2006-09-29	2013-05-27	Ligocyte Pharmaceuticals Inc	Norovirus vaccine formuleringer
PL2134360T3 (pl) *	2007-03-14	2016-05-31	Takeda Vaccines Inc	Oczyszczanie cząstek wirusopodobnych
CN104740624B (zh)	2007-09-18	2018-04-24	武田疫苗股份有限公司	赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
SG2013057732A (en) *	2008-08-08	2015-02-27	Ligocyte Pharmaceuticals Inc	Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010111586A2 (en) *	2009-03-27	2010-09-30	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Mucosal immunization
US20110070260A1 (en) *	2009-09-09	2011-03-24	Baric Ralph S	Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
WO2011079260A2 (en) *	2009-12-23	2011-06-30	Arizona Board Of Regents Acting For And On Behalf Of Arizona State University	Stabilized virus like particles having enhanced mucosal immunogenicity
KR20120125627A (ko) *	2010-01-21	2012-11-16	리고사이트 파머슈티컬즈 인코퍼레이티드	칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
BR112012026116A2 (pt) *	2010-04-15	2016-06-28	Shin Nippon Biomedical Lab Ltd	métodos e composições para liberação intranasal
AU2012244074B2 (en) *	2010-04-15	2015-01-15	Km Biologics Co., Ltd.	Methods and compositions for intranasal delivery
MY170746A (en) *	2011-07-11	2019-08-27	Takeda Vaccines Inc	Parenteral norovirus vaccine formulations
JOP20130186B1 (ar)	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) *	2012-07-11	2014-01-16	Xi Jiang	IgY From Norovirus P Particles And Their Derivatives
SI2939025T1 (sl) *	2012-12-28	2018-09-28	Cellestis Limited	Preizkus celično posredovanega imunskega odziva
US9975923B2 (en)	2013-03-15	2018-05-22	The University Of North Carolina At Chapel Hill	Methods and compositions for norovirus blockade epitopes
WO2014145245A2 (en) *	2013-03-15	2014-09-18	The University Of North Carolina At Chapel Hill	Methods and compositions for norovirus blockade epitopes
JP6479305B2 (ja)	2013-07-12	2019-03-06	株式会社Ｕｍｎファーマ	ウイルス様粒子の精製方法
JP2015017065A (ja) *	2013-07-12	2015-01-29	株式会社Ｕｍｎファーマ	ノロウイルスのウイルス様粒子を含む医薬組成物
JP2015015931A (ja)	2013-07-12	2015-01-29	株式会社Ｕｍｎファーマ	ウイルス様粒子を含む培養物の製造方法
KR20160030961A (ko)	2013-07-17	2016-03-21	다우 글로벌 테크놀로지스 엘엘씨	메틸셀룰로오스를 포함하는 점막에 적용하기 위한 조성물
KR102649950B1 (ko)	2013-10-03	2024-03-22	다케다 백신즈 인코포레이티드	세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
EP3085357B1 (en)	2013-12-16	2019-02-13	Takeda Pharmaceutical Company Limited	Microneedle
AU2016317661B2 (en)	2015-08-28	2023-05-18	Ology Bioservices, Inc.	Norovirus vaccine
KR101914779B1 (ko) *	2016-03-18	2018-11-02	(주)인테라	노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
CN107184970A (zh) *	2017-02-16	2017-09-22	北京生物制品研究所有限责任公司	口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
WO2018182983A1 (en)	2017-03-28	2018-10-04	Children's Hospital Medical Center	Norovirus s particle based vaccines and methods of making and using same
CA3083857A1 (en)	2017-11-30	2019-06-06	Medicago Inc.	Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
EP3752185A1 (en)	2018-02-15	2020-12-23	Icon Genetics GmbH	Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (ja) *	2018-03-06	2020-06-24	株式会社イーダブルニュートリション・ジャパン	貝類のノロウイルス不活化方法
WO2020010428A1 (en)	2018-07-13	2020-01-16	Medicago Inc.	Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
EP3840778A1 (en)	2018-08-20	2021-06-30	Takeda Vaccines, Inc.	Vlp formulations
AU2019344801B2 (en) *	2018-09-17	2025-05-01	Board Of Regents, The University Of Texas System	Compositions and methods for treating bone injury
US11523988B2 (en) *	2018-11-29	2022-12-13	Catalent U.K. Swindon Zydis Limited	Oral dispersible vaccine comprising virosomes
EP3698773A1 (en)	2019-02-21	2020-08-26	Università degli Studi di Parma	Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
MX2021011059A (es)	2019-03-12	2021-10-13	Icon Genetics Gmbh	Particulas tipo norovirus con estabilidad mejorada.
KR20220047332A (ko) *	2019-08-13	2022-04-15	알티뮨 인크.	치료제 효과 및 이의 투여 경로
US20240288407A1 (en) *	2020-06-15	2024-08-29	CureVac SE	Analysis of nucleic acid mixtures
EP4340874A1 (en)	2021-05-21	2024-03-27	Takeda Vaccines, Inc.	Solid composition, freeze-drying method and glass vial
CN115677838A (zh) *	2021-07-29	2023-02-03	成都康华生物制品股份有限公司	六价诺如病毒VLPs疫苗及其制备方法
AU2023235760A1 (en)	2022-03-18	2024-10-24	Denka Company Limited	Virus-like particle containing capsid proteins connected by linker.
WO2025076792A1 (en) *	2023-10-12	2025-04-17	Chengdu Kanghua Biological Product Co., Ltd.	Methods of preparing norovirus vaccine with low amounts of adjuvant
CN117330750A (zh) *	2023-12-01	2024-01-02	北京生物制品研究所有限责任公司	一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6572862B1 (en) *	1989-11-08	2003-06-03	Baylor College Of Medicine	Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) *	1991-03-25	1992-10-01	Genelabs Incorporated	NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
EP0635056A1 (en)	1992-04-08	1995-01-25	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Wild-type measles virus glycoproteins: vaccine and detection method therefor
AU685443B2 (en)	1993-03-23	1998-01-22	Smithkline Beecham Biologicals (Sa)	Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5788970A (en)	1994-03-29	1998-08-04	The University Of Maryland College Park	Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
WO1995031532A1 (en)	1994-05-16	1995-11-23	Merck & Co., Inc.	Papillomavirus vaccines
US5645051A (en) *	1995-04-21	1997-07-08	Dura Pharmaceuticals, Inc.	Unit dose dry powder inhaler
US5861241A (en) *	1995-08-16	1999-01-19	University Of Massachusetts	Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) *	1995-12-07	1996-02-07	Danbiosyst Uk	Vaccine compositions
US5834015A (en)	1996-09-11	1998-11-10	Albany Medical College	Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en)	1996-10-10	1999-09-14	Incyte Pharmaceuticals, Inc.	Project-based full-length biomolecular sequence database
US6491919B2 (en) *	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1259051A (zh)	1997-04-08	2000-07-05	麦克公司	稳定化后的人乳头瘤病毒制剂
JP2002508748A (ja)	1997-05-01	2002-03-19	カイロンコーポレイション	アジュバントとしてのウイルス様粒子の使用
US20040265377A1 (en) *	1997-10-27	2004-12-30	Harry Seager	Solid dispersing vaccine composition for oral delivery
SI1105466T1 (sl) *	1998-08-14	2006-08-31	Merck & Co Inc	Postopek za ciscenje virusu podobnih delcev humanega papilomskega virusa
DE69930960T2 (de)	1998-12-17	2007-04-19	Merck & Co., Inc.	Synthetische virus-ähnliche partikel mit heterologen epitopen.
ES2313881T3 (es)	1999-02-05	2009-03-16	MERCK & CO., INC.	Formulaciones de vacunas frente al papilomavirus humano.
KR100771402B1 (ko)	1999-06-22	2007-10-30	국립감염증연구소장이 대표하는 일본국	Ｓｒｓｖ 검출 킷트
US20040063188A1 (en) *	2002-02-14	2004-04-01	Novavax, Inc.	Kit for treating gastrointestinal tract
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
US7135180B2 (en)	2002-04-11	2006-11-14	Medimmune Vaccines, Inc.	Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
WO2003103605A2 (en)	2002-06-07	2003-12-18	Large Scale Biology Corporation	Flexible vaccine assembly and vaccine delivery platform
DE60335186D1 (de)	2002-06-20	2011-01-13	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
ATE426412T1 (de)	2003-01-30	2009-04-15	Novartis Vaccines & Diagnostic	Adjuvante influenza-vakzine
US20040213745A1 (en)	2003-02-20	2004-10-28	Vincent Sullivan	Powder formulations of rSEB for improved vaccination
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
US7879338B2 (en) *	2003-07-21	2011-02-01	Boyce Thompson Institute For Plant Research	Vectors and methods for immunization against norovirus using transgenic plants
EP1670824A2 (en)	2003-09-24	2006-06-21	Montana State University	Norovirus monoclonal antibodies and peptides
US7795242B2 (en) *	2003-10-15	2010-09-14	The Brigham And Women's Hospital, Inc.	Methods and compositions for immunomodulation
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
FR2863890B1 (fr)	2003-12-19	2006-03-24	Aventis Pasteur	Composition immunostimulante
US7481997B1 (en) *	2004-02-12	2009-01-27	Montana State University	Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) *	2004-05-18	2005-11-24	Goldberg Joanna B	Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es)	2004-09-03	2010-02-23	Ct Ingenieria Genetica Biotech	Composición vacunal contra el virus de la hepatitis c
CA2584228C (en)	2004-10-20	2015-05-05	Acambis Inc.	Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en)	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
KR20070108371A (ko)	2005-01-05	2007-11-09	필라델피아 헬스 앤드 에듀케이션 코퍼레이션	전달 비히클, 생물활성 물질 및 바이러스 백신
US8168771B2 (en)	2005-01-31	2012-05-01	The Johns Hopkins University	Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2006091517A2 (en)	2005-02-18	2006-08-31	Novartis Vaccines And Diagnostics Inc.	Immunogens from uropathogenic escherichia coli
RU2414239C2 (ru)	2005-03-18	2011-03-20	Цитос Биотехнологи Аг	Белки, слитые с кошачьим аллергеном, и их применение
KR20080018176A (ko)	2005-06-01	2008-02-27	다우 글로벌 테크놀로지스 인크.	다가 바이러스 유사 입자 생산 방법
EP1736538A1 (en)	2005-06-21	2006-12-27	Cytos Biotechnology AG	Process for the preparative purification of virus-like-particles (VLPs)
JP5215865B2 (ja)	2005-11-22	2013-06-19	ノバルティスヴァクシンズアンドダイアグノスティクスインコーポレイテッド	ノロウイルス抗原およびサポウイルス抗原
JP2007145775A (ja)	2005-11-29	2007-06-14	Falco Life Science:Kk	ノロウイルスｇｉの高感度検出方法
DK2066354T3 (da)	2006-09-29	2013-05-27	Ligocyte Pharmaceuticals Inc	Norovirus vaccine formuleringer
AU2007330494B2 (en)	2006-12-06	2014-03-13	Seqirus UK Limited	Vaccines including antigen from four strains of influenza virus
PL2134360T3 (pl)	2007-03-14	2016-05-31	Takeda Vaccines Inc	Oczyszczanie cząstek wirusopodobnych
US8474614B2 (en) *	2007-03-14	2013-07-02	BBY Solutions	Protective container for a flat screen monitor
CN104740624B (zh) *	2007-09-18	2018-04-24	武田疫苗股份有限公司	赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
SG2013057732A (en)	2008-08-08	2015-02-27	Ligocyte Pharmaceuticals Inc	Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
JP2012515752A (ja)	2009-01-22	2012-07-12	ファーマシーネ，インコーポレイテッド	安定なワクチン組成物とその使用方法
JP5778039B2 (ja)	2009-02-10	2015-09-16	ノバルティスアーゲー	流行関連株のためのインフルエンザワクチンレジメン
US20110070260A1 (en)	2009-09-09	2011-03-24	Baric Ralph S	Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
KR20120125627A (ko)	2010-01-21	2012-11-16	리고사이트 파머슈티컬즈 인코퍼레이티드	칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
EP2575773A4 (en)	2010-05-26	2014-06-25	Selecta Biosciences Inc	SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
MY170746A (en)	2011-07-11	2019-08-27	Takeda Vaccines Inc	Parenteral norovirus vaccine formulations
JOP20130186B1 (ar)	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات

2007
- 2007-09-28 DK DK07853688.5T patent/DK2066354T3/da active
- 2007-09-28 ES ES13157572.2T patent/ES2577833T3/es active Active
- 2007-09-28 ES ES13157573.0T patent/ES2618885T3/es active Active
- 2007-09-28 HU HUE13157573A patent/HUE032422T2/en unknown
- 2007-09-28 WO PCT/US2007/079929 patent/WO2008042789A1/en not_active Ceased
- 2007-09-28 CA CA2664157A patent/CA2664157C/en active Active
- 2007-09-28 HU HUE13157572A patent/HUE028978T2/en unknown
- 2007-09-28 US US12/093,921 patent/US7955603B2/en active Active
- 2007-09-28 LT LTEP13157573.0T patent/LT2601970T/lt unknown
- 2007-09-28 EP EP13173005.3A patent/EP2641613A1/en not_active Withdrawn
- 2007-09-28 KR KR1020097008725A patent/KR101515489B1/ko active Active
- 2007-09-28 PL PL13157572.2T patent/PL2601969T3/pl unknown
- 2007-09-28 ES ES07853688T patent/ES2420136T3/es active Active
- 2007-09-28 SI SI200731885A patent/SI2601970T1/sl unknown
- 2007-09-28 AU AU2007303608A patent/AU2007303608B2/en active Active
- 2007-09-28 PT PT131575730T patent/PT2601970T/pt unknown
- 2007-09-28 EP EP13157573.0A patent/EP2601970B1/en not_active Revoked
- 2007-09-28 EP EP07853688.5A patent/EP2066354B1/en active Active
- 2007-09-28 EP EP13157572.2A patent/EP2601969B1/en active Active
- 2007-09-28 DK DK13157573.0T patent/DK2601970T3/da active
- 2007-09-28 PL PL13157573T patent/PL2601970T3/pl unknown
- 2007-09-28 JP JP2009530639A patent/JP5476544B2/ja active Active
- 2007-09-28 SG SG10201502490YA patent/SG10201502490YA/en unknown
- 2007-09-28 SG SG2011071123A patent/SG174845A1/en unknown
- 2007-09-28 DK DK13157572.2T patent/DK2601969T3/da active
- 2007-09-28 SG SG10202012986SA patent/SG10202012986SA/en unknown
2010
- 2010-06-16 US US12/816,495 patent/US8431116B2/en active Active
2011
- 2011-12-20 US US13/330,854 patent/US20120093861A1/en not_active Abandoned
2013
- 2013-03-15 US US13/836,446 patent/US10010599B2/en active Active
- 2013-03-15 US US13/837,653 patent/US9308249B2/en active Active
- 2013-03-15 US US13/837,885 patent/US9272028B2/en active Active
- 2013-06-24 JP JP2013131559A patent/JP5898133B2/ja active Active
2015
- 2015-07-10 US US14/796,714 patent/US9861691B2/en active Active
- 2015-10-05 JP JP2015197633A patent/JP6134364B2/ja active Active
2017
- 2017-01-25 CY CY20171100109T patent/CY1118492T1/el unknown
2018
- 2018-05-31 US US15/994,887 patent/US10512682B2/en active Active

Also Published As

Publication number	Publication date
EP2066354A4 (en)	2010-10-20
ES2618885T3 (es)	2017-06-22
US9308249B2 (en)	2016-04-12
ES2420136T3 (es)	2013-08-22
US20080299152A1 (en)	2008-12-04
JP5898133B2 (ja)	2016-04-06
DK2601970T3 (da)	2017-02-06
EP2066354A1 (en)	2009-06-10
CY1118492T1 (el)	2017-07-12
PT2601970T (pt)	2017-02-02
LT2601970T (lt)	2017-04-25
EP2601970B1 (en)	2016-10-26
US7955603B2 (en)	2011-06-07
HUE028978T2 (en)	2017-02-28
US20120156243A1 (en)	2012-06-21
WO2008042789A1 (en)	2008-04-10
JP2013234188A (ja)	2013-11-21
US20120093861A1 (en)	2012-04-19
US20130273148A1 (en)	2013-10-17
CA2664157C (en)	2015-12-01
EP2601970A1 (en)	2013-06-12
EP2066354B1 (en)	2013-04-17
EP2641613A1 (en)	2013-09-25
HUE032422T2 (en)	2017-09-28
JP2016020378A (ja)	2016-02-04
US20160008455A1 (en)	2016-01-14
SG10202012986SA (en)	2021-01-28
AU2007303608A1 (en)	2008-04-10
US20140286994A1 (en)	2014-09-25
JP5476544B2 (ja)	2014-04-23
US9272028B2 (en)	2016-03-01
KR20090079912A (ko)	2009-07-22
US10512682B2 (en)	2019-12-24
SG174845A1 (en)	2011-10-28
US20190125853A1 (en)	2019-05-02
JP2010505766A (ja)	2010-02-25
DK2601969T3 (da)	2016-04-18
SG10201502490YA (en)	2015-05-28
PL2601970T3 (pl)	2017-07-31
US8431116B2 (en)	2013-04-30
PL2601969T3 (pl)	2016-10-31
SI2601970T1 (sl)	2017-04-26
AU2007303608B2 (en)	2013-05-02
HK1184057A1 (en)	2014-01-17
CA2664157A1 (en)	2008-04-10
US9861691B2 (en)	2018-01-09
US20130273105A1 (en)	2013-10-17
KR101515489B1 (ko)	2015-04-30
ES2577833T3 (es)	2016-07-19
US10010599B2 (en)	2018-07-03
JP6134364B2 (ja)	2017-05-24
EP2601969B1 (en)	2016-03-30
EP2601969A2 (en)	2013-06-12
EP2601969A3 (en)	2013-08-21

Publication	Publication Date	Title
DK2066354T3 (da)	2013-05-27	Norovirus vaccine formuleringer
ATE450271T1 (de)	2009-12-15	Impfstoff
DK2068886T3 (da)	2013-11-18	Lipidholdige præparater
DK1968631T3 (da)	2015-06-15	Vaccine
BRPI0814188A2 (pt)	2014-10-14	Formulações
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
PT2889310T (pt)	2018-03-26	Formulações de anticorpo
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
BRPI0908785A2 (pt)	2015-07-28	Formulações herbicida
DK2114993T3 (da)	2012-10-22	Vaccine
EP2098065A4 (en)	2012-04-04	SWARM PICTURE
DK2200646T3 (da)	2013-10-21	RNA-Vacciner
DE602006021235D1 (de)	2011-05-19	Kristallglasgegenstand
BRPI0814314A2 (pt)	2015-05-26	Microbiocidas
CR10571A (es)	2009-05-14	Vacuna virica recombinante
BRPI0917205A2 (pt)	2015-11-10	vacina polivalente
DE602007001937D1 (de)	2009-09-24	Optischer Tomograph
DK2125048T3 (da)	2014-10-13	Præparat
DK2043682T3 (da)	2014-06-02	Influenzavaccine
BRPI0813781A2 (pt)	2019-09-24	microbiocidas
EP2061502A4 (en)	2010-10-20	CARBOHYDRATE-BASED VACCINES FOR HLV
BRPI0809653A2 (pt)	2014-10-07	Formulações líquidas de manoproteína
EP2016414A4 (en)	2009-08-12	T-cell vaccine
BRPI0810835A2 (pt)	2015-06-16	Formulações de hidroquinona ansamicina
ATE454037T1 (de)	2010-01-15	Haltesystem